Chanelle cracks US market

Chanelle Pharma is set to crack the American market with a headline entry into the country’s lucrative market for anti-parasitic health products for domestic pets.

The Loughrea company has just shipped its first products to the US market, following the granting of accreditation by the US Food and Drugs Administration (FDA) for its Spot On manufacturing facility.

And that also will see Chanelle proceed with plans to invest €11 million in a new 25,000 sq ft manufacturing facility for its entry into the US market.

The onerous quality assessment by the FDA, which saw a team of inspectors from the US visit Loughrea, took nearly two years to complete – making Chanelle one of only two companies in Europe to be approved by the FDA to manufacture Spot On for the US market.

Spot On is a topical treatment used globally to protect dogs and cats against harmful parasites.

Michael Burke, managing director, Chanelle Pharma, invested €10 million in the new Spot On facility which was officially opened by Tánaiste Simon Coveney in 2018.

The new 30,000 sq. ft. facility is Europe’s first dedicated Spot On manufacturing facility built to European and US quality standards.

Chanelle Pharma has secured a contract with one of the largest distributors of veterinary products in the US to ship over two million batches of Spot On over the next few months and has already started supplying the US market with product manufactured in Loughrea.

For more, read this week’s Connacht Tribune.

Get the Connacht Tribune Live app

The Connacht Tribune Live app is the home of everything that is happening in Galway City and county. It’s completely FREE and features all the latest news, sport and information on what’s on in your area. Click HERE to download it for iPhone and iPad from Apple’s App Store, or HERE to get the Android Version from Google Play.